BlossomHill Therapeutics, Inc. Common Stock

BlossomHill Therapeutics closed up better than 18% on Wednesday, its strongest one-day performance since its August 7 IPO. The surge followed the company's Tuesday release of updated data from its ongoing Phase 1/2 SOLARA trial of lead program BH-30643 in EGFR-mutant non-small cell lung cancer. As of a May data cutoff, 16 of 40 patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, achieved a confirmed possible response and another two had an unconfirmed response, for an objective response rate of 45% and a disease control rate of 88%, with median follow-up of 6.9 months. BlossomHill said BH-30643 is designed to overcome the limitations of currently approved EGFR inhibitors for the treatment of EGFR-mutant NSCLC. One of the most prescribed therapies for NSCLC is AstraZeneca's Tagrisso, a third-generation EGFR inhibitor with a first-line indication that brought in $3.8B in the first half of 2026.